No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AZNCF ASTRAZENECA PLC
- 145.100
- -0.955-0.65%
15min DelayClose Apr 26 16:00 ET
224.94BMarket Cap35.83P/E (TTM)
150.780High142.650Low55.92KVolume148.325Open146.055Pre Close8.13MTurnover0.00%Turnover Ratio38.08P/E (Static)1.55BShares150.85252wk High6.01P/B224.94BFloat Cap116.32552wk Low2.89Dividend TTM1.55BShs Float150.851Historical High1.99%Div YieldTTM5.57%Amplitude100.044Historical Low145.389Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
AstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts
Press Release: Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order Canada NewsWire HAMILTON, ON and BOSTON, April 25, 2024 HAMILTON, ON and BOSTON, Apr
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca Plc
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $5 to $86,
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Trending Tickers: Microsoft, Google, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's
Alphabet, Microsoft, Southwest Earnings: What to Watch
Comments
Despite strong guidance and pipeline, the stock fell due to disappointment on the quarterly product mix. Analysts were surprised by the weakness versus consensus for several key growth drivers.
AstraZeneca Shares Drop After Weak Quarterly Print Despite 2024 Growth Guidance -- 2nd Update 1
No FDA Approval for FBIO
no news, guys I also reenter after some gains. $Fortress Biotech(FBIO.US$ . but this one actually has a lot of project, sadly it lack of cash and equity. it seems so they issue warrant monthly. DER still high. potential BEP, but a bit worried if per month issued warrant. it has position as stock holder in $Mustang Bio(MBIO.US$, $Journey Medical(DERM.US$ , $Checkpoint Therapeutics(CKPT.US$ .
Hope miracle happens suddenly shows up an acquisition news like $Gracell Biotechnologies(GRCL.US$ by ...
Hope miracle happens suddenly shows up an acquisition news like $Gracell Biotechnologies(GRCL.US$ by ...
2
White House calls for adequate production of RSV vaccines emphasizing the importance of access for families. AstraZeneca admits Beyfortus demand surpasses previous standards, highlighting its market importance amid rising U.S. RSV cases.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg